Atogepant Patent Expiration
Atogepant is Used for preventing migraine attacks in adults. It was first introduced by Abbvie Inc
Atogepant Patents
Given below is the list of patents protecting Atogepant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Qulipta | US12090148 | Treatment of migraine | Jul 29, 2041 | Abbvie |
| Qulipta | US10117836 | Tablet formulation for CGRP active compounds | Jan 30, 2035 | Abbvie |
| Qulipta | US9850246 | Process for making CGRP receptor antagonists | Mar 13, 2033 | Abbvie |
| Qulipta | US8754096 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Jul 19, 2032 | Abbvie |
| Qulipta | US9499545 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Nov 10, 2031 | Abbvie |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Atogepant's patents.
Latest Legal Activities on Atogepant's Patents
Given below is the list recent legal activities going on the following patents of Atogepant.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Apr, 2024 | US9499545 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US9499545 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2024 | US8754096 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US8754096 |
| transaction for FDA Determination of Regulatory Review Period | 30 Jan, 2024 | US9499545 |
| Change in Power of Attorney (May Include Associate POA) Critical | 26 May, 2023 | US9850246 |
| Email Notification Critical | 26 May, 2023 | US9499545 |
| Electronic Review Critical | 26 May, 2023 | US9499545 |
| Change in Power of Attorney (May Include Associate POA) Critical | 26 May, 2023 | US9499545 |
| Electronic Review Critical | 26 May, 2023 | US9850246 |
Atogepant's Family Patents
